Janssen and ViiV’s monthly injectable HIV combo proves non-inferior to daily standard of care

pharmafile | August 15, 2018 | News story | Research and Development HIV, Janssen, ViiV Healthcare, pharma 

Janssen and GSK’s ViiV Healthcare have unveiled strong new Phase 3 data on its two-drug regimen, injected once a month, for the treatment of HIV-1, demonstrating similar efficacy to a standard daily, oral three-drug regimen over a 48 week period, meeting its primary endpoint.

It was shown that HIV patients who had maintained viral suppression for at least six months, on a daily oral regimen comprised of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent, maintained similar rates of viral suppression taking the combination of Janssen’s rilpivirine and ViiV’s cabotegravir compared to the standard regimen.

“These results offer new evidence that suggest this investigational, two-drug, once a month dosing regimen may reduce the impact of treatment on people’s lives,” said Dr Wim Parys, Head of R&D, Global Public Health at Janssen. “This novel approach would signify a much-needed treatment evolution for people living with HIV, moving from dosing 365 days a year to just 12 times per year.”

Full details of the findings of the trial will be presented at an upcoming scientific event. Janssen and ViiV’s regimen is currently not approved for use anywhere in the world.

Matt Fellows

Related Content

Gilead and Merck share data from phase 2 trial of HIV treatment

Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …

ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment

ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, …

GSK enters agreement for license for JNJ-3089 for development of bepirovirsen

GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …

Latest content